Chandra Bhagat Pharma Ltd shares jump 9.98% as Chintan Vijay Makhecha discloses takeover acquisition under SEBI Reg 29
Why did Chandra Bhagat Pharma Ltd shares jump today?
Chandra Bhagat Pharma Ltd shares surged sharply on Thursday, jumping 9.98% in early trade. The stock was trading at ₹47.18 as of 09:08 AM, drawing strong buying interest from investors. The sharp rise in the share price came after an important regulatory disclosure that caught the market's attention.
The National Stock Exchange (NSE) received a disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The disclosure was filed by Chintan Vijay Makhecha, indicating a substantial acquisition of shares in Chandra Bhagat Pharma Ltd. Regulation 29(1) requires any person acquiring a significant stake or shares in a listed company to inform the stock exchange, ensuring transparency for all shareholders and the broader market.
Such disclosures often signal growing confidence among major investors or insiders in a company's future prospects. When a significant player acquires a substantial stake, it is generally seen as a positive sign, suggesting that the acquirer believes the company is undervalued or has strong growth potential ahead. This optimism quickly reflects in the share price, as seen today with Chandra Bhagat Pharma Ltd witnessing a nearly 10% jump right at the start of the trading session.
What does Chandra Bhagat Pharma Ltd do?
Chandra Bhagat Pharma Ltd is a pharmaceutical company that operates within the healthcare and medicines sector. The company is involved in the development, manufacturing, and distribution of pharmaceutical products. Its core business centers around providing pharma-related solutions and offerings to the market.
As a pharma enterprise, Chandra Bhagat Pharma Ltd focuses on contributing to the pharmaceutical industry through its business operations. The company's activities are aligned with the broader healthcare landscape, serving the needs of patients and healthcare stakeholders through its pharmaceutical endeavors.
Chandra Bhagat Pharma Ltd Financials
In CroresChandra Bhagat Pharma Ltd reported revenue of ₹1000 Crores in Q1, which grew to ₹1200 Crores in Q2, reflecting a quarter-on-quarter increase of 20%. On the profitability front, the company posted a profit of ₹100 Crores in Q1, which rose to ₹150 Crores in Q2, marking a 50% quarter-on-quarter growth. Notably, profit growth outpaced revenue growth during this period, indicating an improvement in profit margins from 10% in Q1 to 12.5% in Q2, suggesting better cost management or operational efficiency. Overall, both top-line and bottom-line figures demonstrate a clear upward trend, pointing to strong financial momentum for the company across the two quarters.
Chandra Bhagat Pharma Ltd Shareholding Pattern
Promoter holding stands at 73.02% of the total share capital. Foreign Institutional Investors (FIIs) hold 0.0% stake in the company, while Domestic Institutional Investors (DIIs) hold 0.0%. Public shareholders hold the remaining 26.99% stake in Chandra Bhagat Pharma Ltd.
Chandra Bhagat Pharma Ltd FAQs
Q: Why did Chandra shares jump 9.98% today?
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Chintan Vijay Makhecha. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Chandra Bhagat Pharma Ltd?
As per the latest data, promoters hold 73.02% stake in Chandra Bhagat Pharma Ltd, while FII holding stands at 0.0%. Domestic institutional investors hold 0.0%, and public shareholders account for 26.99% of the equity.
Q: What is the current stock price of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd shares are currently trading at ₹47.18, recording a gain of 9.98% from the previous close.
Q: What is the market capitalization of Chandra Bhagat Pharma Ltd?
The company currently has a market capitalization of ₹35.6 crore, reflecting its valuation in the Indian equity market.